Torrent Pharmaceuticals has launched its Semaglutide brands - Sembolic and Semalix in India, in both oral and injectable formulations. The launch expands the company’s presence in metabolic disorders such as type-2 diabetes and obesity.
The company’s entry into the GLP-1 (glucagon-like peptide-1) therapy segment reflects Torrent’s commitment to expanding treatment options available to healthcare professionals managing complex metabolic conditions at affordable prices. GLP-1 receptor agonists are well-established prescription medications for the management of type 2 diabetes and obesity.
Torrent Pharmaceuticals (Torrent Pharma) is flagship company of the Torrent group, a leader in cardiovascular and central nervous system segments. It also has presence in gastro-intestinal, diabetology, anti-infective and pain management segments.
